

TFU 2627

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents, P.O. Box 1450

Alexandria, VA 22313 on February 21, 2006

*Frank C. Eisenschenk*

Frank C. Eisenschenk, Ph.D., Patent Attorney


FOURTH SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT

Examining Group 1647

Patent Application

Docket No. G-029US04DIV

Serial No. 10/072,159



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Gyan Chandra  
Art Unit : 1646  
Applicants : Bernard Bihain, Lydie Bougueleret, Frances Yen-Potin  
Serial No. : 10/072,159  
Filed : February 5, 2002  
Conf. No. : 2627  
For : Lipoprotein-Regulating Medicaments

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313

FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR §§1.97 AND 1.98

Sir:


In accordance with 37 CFR §1.56, the references listed on the attached form PTO/SB/08 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. A copy of each cited reference is enclosed.

This information is being submitted subsequent to the later of three months after the filing date of the present application or the mailing of the first Office Action on the merits, but before the mailing of a final action or the notice of allowance. Please charge the fee of \$180.00 to Deposit Account No. 19-0065.

It is respectfully requested that the references cited on the attached form PTO/SB/08 be considered in the examination of the subject application and that their consideration be made of record.

Applicants respectfully assert that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statements.

Respectfully submitted,



Frank C. Eisenschenk, Ph.D.

Patent Attorney

Registration No. 45,332


Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: P.O. Box 142950  
Gainesville, FL 32614-2950

FCE/esc

Attachments: Form PTO/SB/08; copies of references cited therein.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	10/072,159
Filing Date	February 5, 2002
First Named Inventor	Bernard Bihain
Group Art Unit	1646
Examiner Name	Gyan Chandra
Attorney Docket Number	G-029US04DIV

Sheet 1 of 1

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R1	GHEBREHIWET, B. "Production and Characterization of a Murine Monoclonal IgM Antibody to Human C1q Receptor (C1qR)" <i>The Journal of Immunology</i> , July 15, 1986, pp. 618-624, Vol. 137, No. 2.	
	R2	GHEBREHIWET, B. <i>et al.</i> "Isolation, cDNA Cloning, and Overexpression of a 33-kD Cell Surface Glycoprotein that Binds to the Globular "Heads" of C1q" <i>The Journal of Experimental Medicine</i> , June 1994, pp. 1809-1821, Vol. 179.	
	R3	JOSEPH, K. <i>et al.</i> "Identification of the Zinc-dependent Endothelial Cell Binding Protein for High Molecular Weight Kininogen and Factor XII: Identity with the Receptor that Binds to the Globular "Heads" of C1q (gC1q-R)" <i>Proceedings of the National Academy of Sciences of the United States of America</i> , August 1996, pp. 8552-8557, Vol. 93.	
	R4	TENNER, A. <i>et al.</i> "Mannose Binding Protein (MBP) Enhances Mononuclear Phagocyte Function via a Receptor that Contains the 126,000 M <sub>r</sub> Component of the C1q Receptor" <i>Immunity</i> , October 1995, pp. 485-493, Vol. 3.	
	R5		
	R6		
	R7		
	R8		
	R9		
	R10		
	R11		
	R12		
	R13		

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.